(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
3 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 14.35%
@ $0.930
发出时间: 14 Feb 2024 @ 22:30
回报率: 23.66%
上一信号: Feb 14 - 02:27
上一信号:
回报率: -2.14 %
Live Chart Being Loaded With Signals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases...
Stats | |
---|---|
今日成交量 | 2.81M |
平均成交量 | 3.12M |
市值 | 193.13M |
EPS | $0 ( 2024-05-02 ) |
下一个收益日期 | ( $-0.170 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.02 |
ATR14 | $0.00600 (0.52%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-11 | Taveras Arthur | Sell | 14 235 | Common Stock |
2024-03-11 | Ragan Paula | Sell | 49 678 | Common Stock |
2024-03-11 | Mostafa Adam S. | Sell | 52 500 | Common Stock |
2024-03-11 | Dibiase Mary | Sell | 15 409 | Common Stock |
2024-02-13 | Arbet-engels Christophe | Buy | 180 816 | Stock Appreciation Right |
INSIDER POWER |
---|
80.21 |
Last 96 transactions |
Buy: 15 169 198 | Sell: 1 336 024 |
音量 相关性
X4 Pharmaceuticals Inc 相关性 - 货币/商品
X4 Pharmaceuticals Inc 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-2.00M (0.00 %) |
EPS: | $-0.570 |
FY | 2023 |
营收: | $0 |
毛利润: | $-2.00M (0.00 %) |
EPS: | $-0.570 |
FY | 2022 |
营收: | $0 |
毛利润: | $-1.99M (0.00 %) |
EPS: | $-1.480 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-3.99 |
Financial Reports:
No articles found.
X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。